Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
María Romina Girotti(Cancer Research Center), Caroline J. Springer(Cancer Research Center)
Cited by 209
Related Papers
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
|Advanced Drug Delivery Reviews|2001|177
A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF
|Cancer Research|2010|25